ENZON INC
8-K, 2000-03-24
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: ANCHOR SERIES TRUST, 24F-2NT, 2000-03-24
Next: APACHE OFFSHORE INVESTMENT PARTNERSHIP, 10-K405, 2000-03-24





                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported) March 24, 2000

                                  ENZON, INC.

             (Exact name of registrant as specified in its charter)



                    Delaware                0-12957            22-237286
         (State or other jurisdiction     (Commission        (IRS Employer
             of incorporation)            File Number)       Identification)



                20 Kingsbridge Road, Piscataway, New Jersey       08854
                  (Address of principal executive offices)      (Zip Code)



        Registrant's telephone number, including area code (732) 980-4500


- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)


<PAGE>


Item 5. Other Events

     On March 24, 2000, Enzon,  Inc. issued a press release,  a copy of which is
attached as Exhibit 99.1 and incorporated by reference herein.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

     (c) Exhibit 99.1 - Press Release dated March 24, 2000.


<PAGE>


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Dated: March 24, 2000


                                                  ENZON, INC.
                                                  ----------------------
                                                  (Registrant)

                                          By:     /S/KENNETH J. ZUERBLIS
                                                  ----------------------

                                                  Kenneth J. Zuerblis
                                                  Vice President, Finance
                                                  and Chief Financial Officer





                                  Exhibit 99.1


       ENZON, INC. RAISES AN ADDITIONAL $12.5 MILLION THROUGH EXERCISE OF
                              OVER-ALLOTMENT OPTION

Piscataway,  New Jersey, March 24, 2000 - Enzon, Inc., (NASDAQ:  ENZN) announced
today that the  underwriters of the Company's  recent public offering have fully
exercised  their  over-allotment  option by purchasing  300,000 shares of common
stock  from the  Company  at $44.50  per  share.  As a result,  Enzon  raised an
additional  $12.5 million in net proceeds.  Total net proceeds to Enzon from the
offering,  including  the  exercise of the  over-allotment  option,  amounted to
approximately $95.7 million,  through the sale of a total of 2,300,000 shares of
common stock. The managing underwriters for the offering are Morgan Stanley Dean
Witter, CIBC World Markets and SG Cowen Securities Corporation.

A  registration  statement  relating  to these  securities  was  filed  with and
declared effective by the Securities and Exchange Commission. This press release
shall not constitute an offer to sell or a  solicitation  of an offer to buy nor
shall  there be any sale of these  securities  in any state in which such offer,
solicitation or sale would be unlawful prior to  registration  or  qualification
under the securities laws of such state.

A copy of the  Prospectus  relating to the offering may be obtained  from Morgan
Stanley Dean Witter, Attn: Prospectus  Department,  1585 Broadway, New York, New
York, 10036-8293,  when available. The registration statement can also be viewed
on the Internet at http://www.sec.gov.




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission